PEDIATRIC ONCOLOGY GROUP PROGRAM

儿科肿瘤学小组计划

• 批准号: 3557053
• 负责人: SAMUEL GROSS
• 金额: $ 15.52万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-01-01 至 1991-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557053
• 关键词: cancer registry /resource; cancer rehabilitation mental health service; cancer risk; child (0-11); cooperative study; cyclophosphamide; drug metabolism; fluorouracil; human T cell leukemia; human subject; human therapy evaluation; lymphoma; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; osteosarcoma; pediatric neoplasm /cancer; pediatric pharmacology; retinoblastoma; rhabdomyosarcoma

With the almost explosive evolution of new data on the nature of tumor biology, the mandate for cooperative groups in the forseeable future becomes increasingly more challenging and complex. Information on tumor biology must be incorporated into the development of feasible group-will and intra(sub) group phase II/III studies. As a result, protocols designed for specific subgroups in acute lymphoblastic leukemia must address T-cell and B-cell subtypes and continue to delve into the nature of pre-B and pre-T subtypes. In AML, efforts must be made to identify risk factors whilst utilizing randomized trials of best available "standard" therapy. In this regard, efforts must be made to evaluate new combinations of proven therapy utilizing new knowledge of (1) drug-drug interaction, (2) efficacy of high or mega-dose therapy, and (3) the role of "cleansing" techniques. Examples of (1) include methotrexate-asparaginase, (2) high dose cytosine arabinoside, and (3) antibody purging. Bone marrow transplantation as a major therapeutic arm deserves intensive evaluation. The University of Florida has developed a most favorable preparative regimen for second remission ALL, as part of an 8 institution POG study which, which it will now apply to first remission high risk ALL. A proposal for marrow transplantation in second remission AML is now available for group use, and bone marrow transplantation is underway in high risk neuroblastoma, and is being piloted locally in Hodgkin's disease, Ewing's sarcoma and non-Hodgkin's lymphoma. Bone marrow cleansing with antibody coated magnetized microspheres directed against neuroblastoma, cALLa(+), ALL and T-cell ALL are underway locally. The University of Florida Bone Marrow Transplantation Unit is also a component of a multi-institution CML transplantation study. In addition to active participation in whole group efforts, ongoing programs in pharmacology and pharmacokinetics will continue in order to design regimens which will address the propitious use of chemotherapeutic agents. Finally, this division has expanded its program to include University Hospital of Jacksonville, has submitted additional institutions for cancer control and has broadened its range of studies in genetics and long term effects.

随着有关肿瘤性质的新数据的几乎爆炸性演变 生物学，在可预见的未来合作团体的任务 变得越来越具有挑战性和复杂。 有关肿瘤的信息 生物学必须纳入可行的群体意愿的发展 和（子）组II阶段/III研究。 结果，协议设计 对于急性淋巴细胞白血病中的特定亚组，必须解决T细胞 和B细胞亚型，并继续深入研究前B和 前T亚型。 在AML中，必须努力确定风险因素 同时利用最佳可用“标准”疗法的随机试验。 在这方面，必须努力评估已验证的新组合 利用（1）药物相互作用的新知识，（2）功效 高剂量疗法或（3）“清洁”技术的作用。 （1）的示例包括甲氨蝶呤 - 天冬酰胺酶，（2）高剂量胞嘧啶 阿拉伯糖苷和（3）抗体清除。 骨髓移植作为 主要的治疗臂值得进行深入评估。 大学 佛罗里达州已经开发了最有利的准备方案 缓解全部，作为8机构POG研究的一部分，这将是 现在适用于第一次缓解高风险。 骨髓的建议 第二次缓解中的移植AML现在可用于组使用，并且 骨髓移植正在高风险神经母细胞瘤中，并且是 在霍奇金氏病，尤因的肉瘤和 非霍奇金的淋巴瘤。 用抗体涂层的骨髓清洗 针对神经母细胞瘤，calla（+）的磁化微球，所有和 T-Cell在本地正在进行中。 佛罗里达大学的骨髓 移植单元也是多机构CML的组成部分 移植研究。 除了积极参与整个小组 努力，在药理学和药代动力学领域的持续计划将 继续设计方案，以解决有机用途 化学治疗剂。 最后，这个部门扩大了 包括杰克逊维尔大学医院的计划已提交 其他用于癌症控制的机构，并扩大了其范围 遗传学和长期影响的研究。